58 results about "Immunological Diagnosis" patented technology

The currently used method for immunological diagnosis of tuberculosis infection, the tuberculin skin test, is problematic for a number of reasons; it has low specificity in BCG vaccinated individuals, a high interobserver variance and requires skill to be read and interpreted. Furthermore it requires an extra visit to the clinic to have the test read. Both people vaccinated with BCG and those exposed to non-tuberculosis mycobacteria give a positive skin test result similar to that seen in a TB infected individual. This also applies for purified protein derivative (PPD) when used in a blood cell based test. The present invention discloses the development of an immunological TB diagnostic tool based on a combination of epitopes from proteins encoded by regions of the M. Tuberculosis (M. tub.) genome, that are not present in the BCG vaccine strain or in the most common non-tuberculosis mycobacteria. Four recently characterized proteins with this diagnostic potential were selected. Peptides from these proteins were tested one by one with peripheral blood mononuclear cells from microscopy or culture confirmed TB patients as well as from healthy BCG vaccinated controls. Some combinations of peptides showed a sensitivity level comparable to the level seen with the two wellknown M. tuberculosisspecific proteins ESAT 6 and CFP 10. An epitope combination with these peptides combined with ESAT 6 and CFP 10 gave a sensitivity of 93%, representing a raise in sensitivity of about 26-33% compared to using ESAT6 or CFP 10 alone. The results from a panel of TB patients, using a collection of the new specific epitopes clearly demonstrates, that addition of other specific epitopes to the already known specific antigens, increases the sensitivity of a diagnostic assay based on cell mediated immune response.

PCT No. PCT / JP95 / 01270 Sec. 371 Date Feb. 26, 1996 Sec. 102(e) Date Feb. 26, 1996 PCT Filed Jun. 26, 1995 PCT Pub. No. WO96 / 00240 PCT Pub. Date Jan. 4, 1996A protein is provided derived from human fibroblast having an N-terminal amino acid sequence represented by SEQ ID NOS: 1 and 2, having a molecular weight of approximately 15kD under reducing and non-reducing conditions by (dosium dodecyl sulfate-polyacrylamide gel electrophoresis), and having an activity to stimulate growth of osteoblast. The protein is produced by gene engineering procedures, contains the amino acid sequence represented by SEQ ID NO: 9 and has osteoblast growth activity. Also provided is a method for preparing the protein by culturing human fibroblast and treating the conditioned medium for purification. The protein is utilized for the treatment of diseases characterized by decreased bone mass such as osteoporosis or is utilized as an antigen for immunological diagnosis of diseases.

The invention relates to a tuberculosis antibody multiple antigen ELISA detection kit and a preparation method thereof, which pertains to the field of tuberculosis medical immunology diagnostic techniques and mainly uses detection antigen, enzyme-linked antihuman IgG antibodies, substrates, positive control serum of tuberculosis patients, control serum of normal person, calf serum and polystyrene microplates to form the kit, wherein, the detection antigen adopts the mycobacterium tuberculosis complex strains of lipid Arabian mannose (LAM), 38kD and 16kD to be combined with arbitrary one or more than one mycobacterium tuberculosis recombinant proteins in the recombinant proteins of MPT63, MTB48 and CFP10-ESAT6. The mycobacterium tuberculosis has high sensitivity, strong specificity and complementarity, can be used for detecting specific antitubercular antibodies in such body fluid samples as serum, hydrothorax and the like, and assisting the diagnosis and differential diagnosis of tuberculosis.

The invention discloses a kit for diagnosing primary hepatoma, preparation method and application thereof. The kit can quickly and accurately carry out the clusterin detection so as to carry out quickauxiliary diagnosis on the primary hepatoma of each period; and the kit especially has an important clinical application value for distinguishing hepatocirrhosis and early liver cancer. The kit comprises an enzyme-linked immunological diagnosis system established on the basis of a double-antibody sandwich principle. The kit has high sensitivity, strong specificity, simple operation, stable reagent, good repeatability, easy popularization and application and extensive market prospect.

The invention discloses a recombination antigen for HFRS diagnosis and its rapid GIA diagnosis indicator paper opposite to shortened NP recombination antigen e112 of Hantaan virus by gene clone technique and simultaneous-detected IgM and IgG antigens in patient serum. The said test paper overcomes the limitation of current HFRS diagnosis method, benefit to early-stage diagnosis, reduces illness death rate, does not requires special device nor professional staff to meet more detection need, and cuts cost greatly.

The invention provides a nano magnetic bead labeled by chicken yolk immune globulin IgY and used for resisting the soluble antigen of schistosoma japonica ovums and a chicken yolk antibody-magnetic bead ELISA (Enzyme-Linked Immuno Sorbent Assay) method for detecting schistosoma japonica circulating antigen. The method comprises the steps of: immunizing a hen with specific antigens of schistosoma japonica with a method of subcutaneous multi-point injection, and extracting, purifying and identifying specific IgY from an egg yolk; and coupling the polyclone IgY on a magnetic bead, and detecting the circulating antigen of the schistosoma by using the magnetic bead-IgY polyclone antibody as a capture antibody and using the specific monoclone IgY antibody as a detecting antibody. The method not only can be used for capturing more antigens by using the magnetic bead and the IgY to increase the sensibility, but also benefits the increase of detecting specificity by using the monoclonal antibody. Thus, the high combination and coordination of sensibility and specificity, required in immunology diagnosis, are realized.

The invention discloses a monoclonal antibody for resisting acidovorax citrulli and application thereof. The monoclonal antibody for resisting the acidovorax citrulli provided by the invention is secreted by a hybridoma cell strain 4C6 for secreting the monoclonal antibody of acidovorax citrulli; the mouse hybridoma cell strain is collected in China General Microbiological Culture Collection Center (CGMCC) with the collection number of CGMCC No.8960. The monoclonal antibody for resisting acidovorax citrulli provided by the invention is good in specificity and high in valence, reacts with different separators of the acidovorax citrulli, and has good broad-spectrum performance. The monoclonal antibody is applied to an acidovorax citrulliserological diagnosis reagent, good in specificity, and avoids cross reaction. The monoclonal antibody for resisting acidovorax citrulli developed by the invention can be used for developing immunological diagnostic reagents such as an ELISA diagnosis reagent, a colloidal gold immune test paper strip, an antibody chip, a biological sensor, and the like, of the acidovorax citrulli.

The invention discloses a secondary sicca syndrome epitope and an application thereof and belongs to the technical field of immunological diagnoses. The epitope is a polypeptide, and the amino acid sequence of the epitope is shown as SEQ ID NO: 1 in the sequence table. By means of an enzyme-linked immunosorbent assay (ELISA), reaction conditions of the epitope polypeptide and patient serums are detected; and according to the detection, the epitope polypeptide can be specifically combined with intravenous gamma globulin (IgG) in the patient serums instead of reacting with serums of healthy persons. The epitope polypeptide can be used for preparing drugs for diagnosing secondary sicca syndromes.

The invention discloses an anti-schistosoma japonicum Sj14-3-3 protein monoclonal antibody and application thereof in immune diagnosis, and belongs to the technical field of immune diagnosis of parasitic diseases. The monoclonal antibody against recombinant Sj14-3-3 protein is generated by hybridoma JYQ5C6-1 which has the collection number of CCTCCC201118. The monoclonal antibody against recombinant Sj14-3-3 protein is applied to the detection of an antibody used by schistosoma infected patients or circulating antigen Sj14-3-3 protein in animal blood in schistosoma infected immune diagnosis. The prepared anti-Sj14-3-3 protein molecular specific monoclonal antibody can be used for establishing various immunological diagnosis methods for detecting anti-Sj14-3-3 protein circulating antigens. The time fluorescence resolution method for detecting circulating antigen Sj14-3-3 protein, established by using the anti-Sj14-3-3 protein specific monoclonal antibody, can further improve the accuracy and the positive rate of detecting the schistosoma circulating antigen Sj14-3-3 protein, and has good application prospect.

The invention provides a recombinant protein of a mycobacterium tuberculosis specific marker Rv 3120. The recombinant protein comprises an amino acid sequence as shown in SEQ ID NO.1. The invention also provides a coding nucleotide sequence of the recombinant protein of the mycobacterium tuberculosis Rv 3120, a preparation method of the recombinant protein, and an application of the recombinant protein. According to the invention, a mycobacterium tuberculosis immunodominant antigen Rv 3120 is first reported on the basis of the research results of immunomics. The mycobacterium tuberculosis immunodominant antigen Rv 3120 is applied to the cellular immunological diagnosis of tuberculosis, and has relatively high sensibility; and moreover, compared with conventional skin test, the mycobacterium tuberculosis immunodominant antigen Rv 3120 has the advantages of faster performance, safety and reliability.

The invention discloses an epitope for sicca syndrome and application thereof, and belongs to the technical field of immunological diagnosis. The epitope is a polypeptide, and an amino acid sequence of the epitope is shown as SEQ ID NO: 1. The epitope is the polypeptide, and enzyme-linked immunosorbent assay (ELISA) detection and the reaction condition of the blood serum of patients indicate that the epitope can be combined with immunoglobulin G (IgG) in the blood serum of the patients specifically and is not reacted with healthy blood. The epitope polypeptide can be used for preparing medicines for diagnosing sicca syndrome.

The invention provides a transgenic animal having within its genome a transgene construct for gastrointestinal tract specific expression of a protein. In a preferred embodiment, the protein is a phytase or a homologue thereof. Such proteins may be heterologous and may be specifically expressed in the salivary gland of the animal by operably linking the nucleic acid sequence encoding the protein with regulatory sequence including a salivary gland protein promoter / enhancer. Also provided are methods of expressing and producing proteins using such nucleic acid constructs. Further, antibodies specific to such proteins and immunological diagnostic kits are also provided.

The invention belongs to the field of biomedical researches and clinical application, and particularly relates to a specific method for quickly and serologically detecting babesiasis with high throughput based on micro-fluidic chips and application thereof. The method for detecting the serum antibody of a babesia antigen in the serum of a babesiasis patient is provided based on the micro-fluidic chips. Comparison and verification with traditional serology including an enzyme linked immunosorbent assay prove that the diagnosis result of the method for serologically detecting babesiasis based on micro-fluidic chips is consistent with that of traditional serology. Furthermore, the method has the characteristics of low serum sample usage, multi-antigen detection, low reagent and energy consumption, low detection cost, high automatic degree and prevention of pollution among samples. The method can further provide a magnificent reference base for serum immunological diagnosis of patients with babesiasis.

The invention relates to a preparation method of antiserum, and in particular to a preparation method and application of Koi herpes virus antiserum. The preparation method comprises the following steps: selecting healthy Koi as an experimental animal, collecting purified Koi herpes virus antigens, subcutaneously injecting at multiple points of the back of the Koi, when a serum titer reaches a peak value, sampling a great amount of blood from heart or caudal veins, separating serum, measuring a titer, split charging, freezing, and storing. The obtained Koi herpes virus antiserum is used for detecting a KHV (Koi herpes virus) antigen and can be used as positive serum of the KHV antibody detection method. According to the preparation method of the Koi herpes virus antiserum, a preparation method of Koi KHV resistant antiserum is established, the high-titer antiserum is obtained, and the obtained antiserum can be used for detecting the KHV antigen in methods such as IFAT, ELISA and the like and can be used as the positive serum to detect the KHV antibody. A programmed antiserum preparation method is provided for performing the KHV or KHV antibody immunology diagnosis in China, and a finished product immunology diagnosis reagent can be provided.

The invention relates to an indirect ELISA kit for cat toxoplasma gondii serum antibody and a preparation method thereof. The toxoplasma gondii in serum is detected by adopting toxoplasma gondii surface protein SAG3 as a coating antigen; an indirect ELISA method is established by adopting HRP marked goat anti-cat IgG as a detection antibody, which has relatively strong specificity, sensitivity and repeatability; according to the invention, except for the fact that the washing liquid is powder, the main reagents can be directly applied after being dissolved in water; for the kit, the laboratory detection washing liquid is used as a basic solution, and the rest all exists in a form of liquid working solution, thus the kit is convenient to use; and the invention provides a convenient and reliable immunological diagnosis method for large sample detection and epidemiological survey and provides a basis for the diagnosis of cat toxoplasmosis.

The present invention discloses HBV-DNA kit for quantitative enzyme-linked immunological measurement of hepatitis B core antigen and its preparation process, and belongs to the field of molecular biology and immunological diagnosis reagent. The kit includes: fluorescent quantitative HBV-DNA serum standard, HBsAb polyclonal antibody pre-coated standard enzyme reaction strip, HBcAb polyclonal antibody pre-coated standard enzyme reaction strip, diductor, enzyme labeling core antibody, substrate developer, positive contrast, negative contrast and terminating liquid. The present invention can measure HBV-DNA content in serum specifically and accurately, and has the advantages of simple operation, high sensitivity, high specificity, high stability, etc.

The invention relates to a cell and protein combined analysis device and combined analysis method, and the device comprises a sample storage unit for carrying one or more whole-blood samples; an automatic sample feeding unit for sample loading, sample transferring and reagent addition operation; a cell analysis unit for classifying and counting cells of the sample; a protein analysis unit for protein biochemical and immunological detection of the sample; and a data processing unit for controlling automatic sample feeding operation, real-time collection of analysis results of the cell analysis unit and the protein analysis unit and display of processed results. Cell analysis and protein analysis are integrated in one device, automatic cell and protein combined analysis can be realized, and the cell and protein combined analysis device and combined analysis method have the advantages of high flux and simple operation, and can meet the clinical needs of simultaneous cell diagnosis and biochemical and immunological diagnosis of the blood samples.

The invention relates to a method for preparing a homodimer protein mixture by using repulsive interaction of charges. The method comprises the step of replacing part of residues with the opposite-charged residues, so that different proteins or antibodies are unfavorable to forming heterodimers due to the repulsive interaction between like charges, while same proteins or antibodies are favorable to forming homodimers due to attractive interaction between opposite charges. The homodimer protein mixture obtained according to the method of the invention can simultaneously act on different epitopes of the same target, and simultaneously inhibit the effects of a plurality of antigens by binding to the antigens from different sources, thereby providing a new approach towards immunological diagnosis and treatment of tumors and other diseases.

The invention discloses diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis. The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic re agents of the present invention can replace former mixtures / cocktails / pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.

The present invention relates to specific skin reagent for diagnosing tuberculous infection and active tuberculosis, and belongs to the field of medical immunological diagnosis technology. The specific skin reagent consists of diluent liquid and dissolved tuberculous allergen, and the tuberculous allergen is tuberculous mycobacterium ESAT6 protein. The present invention also proposes applying tuberculous mycobacterium ESAT6 protein for human skin test as tuberculous allergen to detect tuberculous infecting person and tuberculosis patient and identify the specific reaction of inoculated Calmette-Guerin bacillus vaccine. The present invention can induce the immune response of tuberculous infecting person. The reagent can induce delayed allergic reaction of tuberculous infecting person and can identify BCG inoculation from the allergic reaction of non-tuberculous mycobacterium and tuberculous mycobacterium infection.

The invention provides a transgenic animal having within its genome a transgene construct for gastrointestinal tract specific expression of a protein. In a preferred embodiment, the protein is a phytase or a homologue thereof. Such proteins may be heterologous and may be specifically expressed in the salivary gland of the animal by operably linking the nucleic acid sequence encoding the protein with regulatory sequence including a salivary gland protein promoter / enhancer. Also provided are methods of expressing and producing proteins using such nucleic acid constructs. Further, antibodies specific to such proteins and immunological diagnostic kits are also provided.

The invention discloses a monoclonal antibody for anti-XA21 protein and use thereof. The monoclonal antibody for anti-XA21 protein is secreted by a hybridoma cell line 60632-18, and the registered number of the hybridoma cell line 60632-18 in the China General Microbiological Culture Collection Center of China Committee for Culture Collection of Microorganisms is CGMCC No. 10416. The monoclonal antibody for the anti-XA21 protein is good in specificity and high in titer. The monoclonal antibody for the anti-XA21 protein can be used for developing immunology diagnostic reagents of the anti-XA21 protein, such as enzyme-linked diagnostic reagents, colloidal gold immunostrips, antibody chips and biosensors and the like.

The invention discloses a mycobacterium tuberculosis Rv3457c recombinant protein as well as a preparation method and application thereof. The amino acid sequence of the mycobacterium tuberculosis Rv3457c recombinant protein is expressed as SEQ ID NO:1. The invention also provides an encoding nucleotide sequence of the mycobacterium tuberculosis Rv3457c recombinant protein and a preparation method of the recombinant protein. The invention firstly reports a mycobacterium tuberculosis immunodominance antigen Rv3457c based on the research achievement of the immunomics. The mycobacterium tuberculosis immunodominance antigen Rv3457c is applied to cellular immunological diagnosis of the tuberculosis and has higher sensitivity; compared with the conventional skin test, the mycobacterium tuberculosis immunodominance antigen Rv3457c is relatively rapid, safe and reliable.

A novel protein and a process of producing the protein is provided. The protein is a glycoprotein having activity of suppressing the differentiation and / or maturation of adipocyte, having a molecular weight of about 45 kD under non-reducing conditions and about 28 kD and / or 23 kD under reducing conditions, and exhibiting affinity to heparin. A process of producing the protein comprising culturing human fibroblasts and purifying the culture broth by chromatography using an ion exchange column, affinity column, and reverse phase column.A cDNA encoding the protein and a process of producing the protein using the cDNA are also provided. The protein of the present invention is useful as a pharmaceutical composition for preventing or treating obesity or as an antigen for establishing immunological diagnosis, etc.

The invention relates to a schistosome antigen for inducing short-lived antibody response and a schistosomiasis diagnostic kit and a detection method for detecting the antibody response, belonging to the technical field of schistosomiasis prevention and treatment and immunological diagnosis. Protein molecules such as glyceraldehyde-3-phosphate dehydrogenase (SjGAPDH) and the like capable of inducing short-lived antibody response in a schistosomiasis infected person through an immunoblotting technology and a mass spectrometry method are identified. A recombinant SjGAPD protein is prepared by adopting a genetic engineering technology, and an enzyme-linked immunosorbent assay detection kit and detection method for detecting anti-SjGAPDH protein specific short-lived antibody response in the schistosomiasis infected person by the recombinant SjGAPD protein are established to diagnose the schistosomiasis infected person and estimate the treatment effect.

The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic re agents of the present invention can replace former mixtures / cocktails / pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.

The invention relates to the field of aquatic animal disease control and in particular relates to a preparation method and an application of an EHNV (Epizootic Haematopoietic Necrosis Virus) antiserum. The preparation method of the EHNV antiserum comprises the steps of preparing a high-purity antigen, purifying and carrying out immunization so as to obtain the EHNV antiserum. With the adoption of the preparation method of the EHNV antiserum, the EHNV antiserum is prepared. According to the preparation method, as a low-speed long-time centrifugation method is adopted, high-concentration EHNV (purified virus) is obtained, the immune operation is carried out on an experimental animal with the high-concentration EHNV as an antigen, and a foundation of preparing the antiserum with strong specificity and high titer is laid; the problems in China EHNV detection technology that an immunology diagnostic reagent is high dependent on import, the detection cost is high and the like are solved, and an EHNV immunology diagnostic method is beneficial to popularization and application.

The invention provides C-peptide immunogen. The C-peptide immunogen comprises a first complete antigen and a second complete antigen, wherein the first complete antigen is obtained by coupling a C-peptide N-terminal amino acid sequence and carrier protein; the second complete antigen is obtained by coupling a C-peptide C-terminal amino acid sequence and carrier protein; and the C-peptide N-terminal amino acid sequence of the first complete antigen is the 1st-12th site sequence in a C-peptide overall length sequence, and the C-peptide C-terminal amino acid sequence of the second complete antigen is the 18st-31st site sequence in the C-peptide overall length sequence. Through a conventional synthesis method, the antigens can be obtained, and are usable complete antigens. The preparation method is simple, and the obtained complete antigen is stable in structure. The monoclonal antibody pair obtained by animal immunization can respectively realize specific binding of the N terminal and theC terminal of C peptide, and the distance of binding sites is far, so that the condition that pairing cannot be performed caused by space steric hindrance can be avoided, and the requirements for development of antibodies for a C-peptide magnetic particle chemical light-emitting immunoreagent and other immunology diagnosis reagents can be met.

The invention provides a hybridoma cell strain, and belongs to the technical field of monoclonal antibody (MAb) preparation. The hybridoma cell strain disclosed by the invention can secrete avian-likeH1N1 swine influenza virus HA protein MAb, and the obtained MAb has the characteristics of good specificity, high titer and the like. By utilizing the MAb and combining a peptide scanning technology,the linear epitope 216VSVGSS221 located on the HA protein is obtained through screening, and the epitope is highly conservative in the avian-like H1N1 virus. The MAb and the epitope can be obtained to be used for establishing immunological diagnosis methods of the avian-like H1N1 SIV or the antibody thereof, such as ELISA, colloidal gold and the like. The HA protein epitope information of the H1N1 SIV can be perfected by obtaining the epitope information, the structure and the function of the HA protein antigen can be better understood, and theoretical and technical supports are provided forpredicting the dynamic state of virus antigenic variation and better preventing and controlling epidemic diseases.